Interaction of cardiac troponin with cardiotonic drugs: a structural perspective
Monica X Li1, Ian M Robertson, Brian D Sykes
1Department of Biochemistry, University of Alberta, Edmonton, Alta., Canada.
Abstract:
Over the 40 years since its discovery, many studies have focused on understanding the role of troponin as a myofilament based molecular switch in regulating the Ca(2+)-dependent activation of striated muscle contraction. Recently, studies have explored the role of cardiac troponin as a target for cardiotonic agents. These drugs are clinically useful for treating heart failure, a condition in which the heart is no longer able to pump enough blood to other organs. These agents act via a mechanism that modulates the Ca(2+)-sensitivity of troponin; such a mode of action is therapeutically desirable because intracellular Ca(2+) concentration is not perturbed, preserving the regulation of other Ca(2+)-based signaling pathways. This review describes molecular details of the interaction of cardiac troponin with a variety of cardiotonic drugs. We present recent structural work that has identified the docking sites of several cardiotonic drugs in the troponin C-troponin I interface and discuss their relevance in the design of troponin based drugs for the treatment of heart disease.
Insights
Cardiac troponin regulates muscle contraction and is a target for heart failure drugs. New research reveals drug binding sites on troponin, aiding the development of novel cardiotonic agents.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- Troponin's role as a molecular switch in Ca(2+)-dependent muscle contraction is well-established.
- Cardiac troponin is increasingly recognized as a therapeutic target for cardiotonic agents used in heart failure treatment.
Purpose of the Study:
- To review the molecular interactions between cardiac troponin and various cardiotonic drugs.
- To present recent structural findings on drug docking sites within the troponin complex.
- To discuss the implications for designing new troponin-based therapeutics for heart disease.
Main Methods:
- Literature review of studies on troponin function and cardiotonic agents.
- Analysis of recent structural biology research identifying drug-binding interfaces.
- Discussion of structure-activity relationships for troponin-modulating drugs.
Main Results:
- Cardiotonic agents modulate troponin's Ca(2+)-sensitivity without altering intracellular Ca(2+) levels.
- Structural studies have pinpointed specific drug docking sites at the troponin C-troponin I interface.
- These findings provide a molecular basis for understanding drug efficacy and guiding future drug design.
Conclusions:
- Understanding troponin-drug interactions is crucial for developing effective cardiotonic therapies.
- Targeting the troponin complex offers a promising strategy for treating heart failure.
- Future drug design efforts can leverage structural insights to create more specific and potent cardiotonic agents.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:13Structure of Cardiac Muscles
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
01:16Actin and Myosin in Muscle Contraction
01:29Pathophysiology of Cardiac Performance
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...